Health News

team of researchers led by Keck School of Medicine of the University of Southern California (USC) oncologist Heinz-Josef Lenz, M.D., has identified a genetic marker that may predict which patients with rectal cancer can be cured by certain chemotherapies when combined with surgery.

Read more

Filed under: Pharmacy News
Tags: cancer, Genetic, medicine, Pharmacy, Surgery

Related posts

• Video: Zometa(R) Reduces Risk of Breast Cancer Recurrence in Premenopausal Women, Study in The New England Journal of Medicine Reports (0)
  A newly published study in The New England Journal of Medicine shows that in premenopausal women with early breast cancer administering Zometa(R) (zoledronic acid) along with post-surgery hormone therapy provided a reduction in risk of recurrence or death that was 36% beyond that achieved with hormone therapy alone(1). Read more [tags] Pharmacy News [/tags]
  
  
• Scientists Rediscover Gene Target For Cancer Therapy (0)
  Epeius Biotechnologies Corporation, an emerging leader in the field of targeted genetic medicine, gained international validation of the cutting-edge science behind its lead oncology product, Rexin-G, when scientists around the world rediscovered the Cyclin G1 gene to be a major locus of cancer pathogenesis and disease progression, and thus a prime target for anti-cancer therapies... Read [...]
  
  
• Results In ‘The New England Journal Of Medicine’ Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery (0)
  Newly published data in The New England Journal of Medicine affirm five-year upfront use of Femara((R)) (letrozole tablets) following surgery as an optimal treatment approach versus tamoxifen for postmenopausal women with early stage breast cancer (hormone-receptor positive). Read more [tags] Pharmacy News [/tags]
  
  
• NYT Examines Challenges To Improving ‘Personalized Medicine’ For Breast Cancer, Other Diseases (0)
  The New York Times on Tuesday examined how improvements in genetic testing could affect "personalized medicine" for the treatment of breast cancer and other diseases in the future. Personalized medicine uses genetic screening and other tests to provide physicians with more information to tailor patients' treatments, the Times reports. Read more [tags] Pharmacy News [/tags]
  
  
• New predictive medicine product for hereditary pancreatic and related cancers (0)
  Myriad Genetics, Inc. today announced the launch of PANEXIA™, a predictive medicine product for hereditary pancreatic and related cancers. PANEXIA is a comprehensive analysis of the PALB2 and BRCA2 genes for assessing a person's risk of developing pancreatic cancer later in life. PANEXIA, Myriad's ninth molecular diagnostic product, is the second product launched by the [...]